Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Exosomal non-coding RNAs: a new avenue for treating diabetic foot ulcers

Chen G., Chen G., Lu J., Hu S.

Clinical Trial on Diabetic Foot, Chronic Wound, published in Front Mol Biosci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Mol Biosci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41438998
PMCID
PMC12719090
DOI
10.3389/fmolb.2025.1701879
Citations
1

Abstract (original English)

Diabetic foot ulcer (DFU) is a severe complication resulting from diabetes mellitus (DM) that affects approximately 18.6 million individuals annually and has a lifetime incidence of up to 25% among DM patients. These ulcers often precede lower-extremity amputations and are associated with high mortality as well as economic burden that necessitate innovative therapeutic strategies beyond conventional methods. Recent research efforts have highlighted the potential of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), that regulate gene expression and cellular functions critical for wound healing. Exosomes are the natural carriers of ncRNAs and offer a promising avenue for the treatment of DFU by enhancing the stabilities and bioavailabilities of these molecules. In this review, we explore the substantial potential of ncRNAs in DFU treatment by emphasizing the action mechanisms of ncRNAs, refinement of exosome-based delivery systems, and expansion of clinical trials to translate ncRNA-based therapies into clinical practice. The application of exosomal ncRNAs involves diverse strategies through different mechanisms, although there remain challenges in terms of exosome preparation consistency, functional enhancement, and efficient drug delivery. The future directions in this regard include optimizing isolation techni

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research